Brief: Syndax to Initiate NDA Submission of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia
24/10/2023 12:10
Oct 24 (Reuters) - Syndax Pharmaceuticals Inc SNDX.O :
* SYNDAX TO INITIATE NDA SUBMISSION OF REVUMENIB IN
RELAPSED/REFRACTORY KMT2AR ACUTE LEUKEMIA UNDER FDA'S REAL-TIME
ONCOLOGY REVIEW PROGRAM
* SYNDAX PHARMACEUTICALS INC: PLANS TO INITIATE NDA
SUBMISSION
IMMINENTLY AND EXPECTS TO COMPLETE SUBMISSION BY YEAR-END 2023
Source text for Eikon: ID:nPn4L67V7a
Further company coverage: SNDX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Syndax Pharmaceuticals
See all newsBrief: Syndax Announces Topline Results From Maxpire Phase 2 Trial Of Axatilimab In Idiopathic Pulmonary Fibrosis
Syndax says mid-stage trial of lung disease treatment fails main goal, ends development
Syndax Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Syndax Q2 revenue jumps 92% on Revuforj, Niktimvo demand
Brief: Syndax Pharmaceuticals Q2 Operating Income USD -39.995 Million